Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alphagan Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 3:06 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Exploring New and Next Generation Ultrasound Technologies for Medical Education, Patient Care, and New Indications

NCT03486444
View directory record Official record
Conditions
Portable Ultrasound
Interventions
Phillips Lumify Diagnostic Ultrasound System, Surveys
Diagnostic Test · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

NCT01229410
View directory record Official record
Conditions
Vitrectomy
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine, placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 20, 2026, 3:06 PM EDT
Completed No phase listed Observational

Testing Automated Echocardiography

NCT04943965
View directory record Official record
Conditions
This Study is Being Conducted to Collect Echocardiographic Data to Test the Lumify Ultrasound With Hemodynamic Automation Device
Interventions
Ultrasound imaging
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 20, 2026, 3:06 PM EDT
Completed No phase listed Observational

Handheld Ultrasound (HHUS) for Home Use in Hemophilia

NCT04131920
View directory record Official record
Conditions
Joint Bleed, Hemophilia A
Interventions
handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
Device
Lead sponsor
Washington Institute for Coagulation
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 20, 2026, 3:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

NCT00413751
View directory record Official record
Conditions
Healthy
Interventions
Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional

Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients

NCT00352807
View directory record Official record
Conditions
Cataract
Interventions
Brimonidine Purite
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
4
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332345
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00061529
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Results available

24-hour IOP-lowering Effect of Brimonidine 0.1%

NCT00457795
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
brimonidine 0.1% (Alphagan® P)
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Results available

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

NCT03323164
View directory record Official record
Conditions
Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions
Timolol Maleate, Brimonidine Tartrate
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

NCT00693485
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

NCT00317577
View directory record Official record
Conditions
Glaucoma, Open Angle
Interventions
brimonidine, timolol
Drug
Lead sponsor
Chicago Center for Vision Research
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
12
States / cities
Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2006 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Results available

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

NCT00811850
View directory record Official record
Conditions
Glaucoma
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
30 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

NCT00652483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Brimonidine ophthalmic solution 0.1%, Brimonidine ophthalmic solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Results available

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

NCT01525173
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

NCT00697541
View directory record Official record
Conditions
Erythematous Rosacea
Interventions
0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Results available

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

NCT00735449
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05728944
View directory record Official record
Conditions
Presbyopia, Near Vision, Refractive Error, Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Dothan, Alabama • Scottsdale, Arizona • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

NCT01080209
View directory record Official record
Conditions
Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Interventions
Brimo PS DDS®, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

NCT00651612
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 20, 2026, 3:06 PM EDT
Active, not recruiting Phase 4 Interventional

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

NCT05127109
View directory record Official record
Conditions
Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions
Nutrition Ecosystem pathway, Comparator
Combination Product · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 3:06 PM EDT